Kashiv BioSciences, LLC

Just ahead of Alvotech publishing its annual results, the biosimilars developer has revealed a first filing for its AVT23 proposed biosimilar to Xolair (omalizumab). In conjunction with partner Advanz

Not to be outdone by recent disclosures from Dr Reddy’s Laboratories, Kashiv Biosciences has announced successful results from a Phase I clinical trial for the firm’s proposed biosimilar to Orencia (a

Amneal Pharmaceuticals is adding a biosimilar rival to Xolair (omalizumab) to its biosimilars pipeline, with the Kashiv Biosciences -developed product becoming the eighth biosimilar in the firm’s po

Aurobindo Pharma ’s subsidiary CuraTeQ Biologics has completed a Phase I trial investigating its BP11 biosimilar candidate to Genentech / Novartis ’ Xolair (omalizumab), bringing the Indian company c